Beigene, Ltd. (NASDAQ:ONC - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Beigene in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($5.51) per share for the year, up from their previous estimate of ($5.98). The consensus estimate for Beigene's current full-year earnings is ($5.83) per share. Leerink Partnrs also issued estimates for Beigene's Q4 2024 earnings at ($0.82) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.46 EPS, FY2025 earnings at $0.14 EPS, FY2026 earnings at $7.33 EPS and FY2027 earnings at $12.83 EPS.
Beigene Stock Down 1.7 %
Shares of NASDAQ ONC traded down $3.83 during mid-day trading on Monday, hitting $219.67. The stock had a trading volume of 292,756 shares, compared to its average volume of 331,102. Beigene has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company has a market cap of $21.47 billion, a price-to-earnings ratio of -26.66 and a beta of 0.63.
Beigene Company Profile
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
See Also
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
